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Abstract: Bovine tuberculosis (TB) in Great Britain adversely affects animal health and welfare and 
is a cause of considerable economic loss. The situation is exacerbated by European badgers (Meles 
meles) acting as a wildlife source of recurrent Mycobacterium bovis infection to cattle. Vaccination of 
badgers against TB is a possible means to reduce and control bovine TB. The delivery of vaccine in 
oral bait holds the best prospect for vaccinating badgers over a wide geographical area. There are 
practical limitations over the volume and concentration of Bacillus of Calmette and Guérin (BCG) 
that can be prepared for inclusion in bait. The production of BCG in a bioreactor may overcome 
these issues. We evaluated the efficacy of oral, bioreactor-grown BCG against experimental TB in 
badgers. We demonstrated repeatable protection through the direct administration of at least 2.0 × 
108 colony forming units of BCG to the oral cavity, whereas vaccination via voluntary consumption 
of bait containing the same preparation of BCG did not result in demonstrable protection at the 
group-level, although a minority of badgers consuming bait showed immunological responses and 
protection after challenge equivalent to badgers receiving oral vaccine by direct administration. The 
need to deliver oral BCG in the context of a palatable and environmentally robust bait appears to 
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introduce such variation in BCG delivery to sites of immune induction in the badger as to render 
experimental studies variable and inconsistent. 
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1. Introduction 
Bovine tuberculosis (TB) in Great Britain adversely affects animal health and welfare and is a 
cause of considerable economic loss to farmers and Government [1]. Although transmission of the 
bacterium, Mycobacterium bovis between cattle is an important factor in spread of the disease [2], the 
European badger (Meles meles) represents an additional wildlife source of recurrent M. bovis infection 
to cattle in both the United Kingdom (UK) and Ireland [3]. Vaccination of badgers against TB is a 
possible means to reduce and control bovine TB alongside other control measures, including the 
vaccination of cattle in the future. Delivery of vaccine to badgers in oral bait holds the best prospect 
for vaccinating badgers over a wide geographical area [4] and has proved highly successful for mass 
vaccination of other wildlife species against rabies and classical swine fever in mainland Europe [5,6]. 
Success is dependent on combining a vaccine that is safe and efficacious via the oral route with attractive 
bait that can be delivered using a pragmatic and economical deployment protocol. Several studies 
report the successful development of an oral bait for use with wild badgers that is both attractive and 
highly palatable, as well as being compatible with the live, attenuated Bacillus of Calmette and Guérin 
(BCG) vaccine [7–9]. The vaccine itself has been shown to be efficacious when given orally to badgers, 
followed by experimental challenge with virulent M. bovis [10,11]. 
Conventional production of BCG is based on growth as a surface pellicle on liquid medium, 
followed by harvesting and ball-milling to generate a homogeneous suspension of live bacteria [12]. 
Although BCG licensed for parenteral administration to humans and badgers is produced this way, 
there is increasing interest in the possibility of producing the BCG vaccine through cultivation in 
bioreactors [12,13]. This approach has several advantages over conventional production, particularly 
the prospect of rapid, reproducible vaccine production under defined and strictly controlled 
conditions. The success of oral BCG vaccination in experimental challenge studies appears to be 
highly dependent on the dose of BCG administered but there is limitation on the concentration of 
BCG that can be prepared for inclusion in the candidate bait developed in the UK [8]. This is the result 
of constraint on the volume of BCG that can be incorporated in the candidate bait, together with the 
relatively high number of viable BCG needed to confer reliable protection when given orally. For these 
reasons, a further attraction of growing BCG in bioreactors for our context is the possibility of more 
cost-effective production of BCG at volumes and concentrations that exceed what is possible through 
pellicle growth. 
Changing the method of vaccine preparation may introduce changes to the properties of the 
vaccine, including immunogenicity and reactogenicity [14], although these differences may be very 
slight [13]. We were interested therefore in the efficacy of BCG produced in a bioreactor as an oral 
preparation for vaccination of badgers against TB. Across two studies, we demonstrated reproducible 
protection achieved through the direct administration of at least 2.0 × 108 colony forming units (CFU) 
of bioreactor-grown BCG Danish to the oral cavity of badgers, followed thirteen weeks later by 
endobronchial challenge with M. bovis. In contrast, vaccination via voluntary consumption of bait 
containing the same preparation of BCG did not result in demonstrable protection at the group-level. 
At the level of the individual animal however, we saw that where immunity was adequately induced 
there was subsequent protection from challenge. The need to deliver oral BCG in the context of a 
palatable and environmentally robust bait appears to introduce such variation in BCG delivery to 
sites of immune induction in the badger as to render experimental studies variable and inconsistent. 
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2. Materials and Methods 
2.1. Reagents 
Ingredients of Middlebrook 7H9 (TSE compliant): 7H9 broth base (BD Difco, Wokingham, UK, 
Cat no: 271310), 10% v/v OADC supplement (BD BBL, BD Difco, Wokingham, UK, Cat no: 212240), 
0.5% v/v Glycerol (VWR International, Radnor, USA, Cat no: 49779-1 L), 0.2% v/v Tween 80 (Merck 
Life Science UK Limited, Gillingham, UK, Cat no: P6224-500 mL). The medium was prepared as 
follows: 4.7 g of broth base was added to 900 mL water along with 5 mL Glycerol and 2 mL Tween80. 
The broth was autoclaved at 124 °C for 20 min, being allowed to cool prior to adding 100 mL OADC. 
2.2. Preparation of Working Seed 
The inoculum used for generation of a working seed was prepared as follows: four plates of 
Middlebrook 7H10 were spread with M. bovis BCG from commercial vaccine stock (Danish 1331, AJ 
Vaccines, Copenhagen, Denmark) and incubated for four weeks. The biomass from two of these agar 
plates was re-suspended in 20 mL of sterile water and used as the inoculum for bioreactor-growth in 
2 L of Middlebrook 7H9 medium (as described below). For preparation of the working seed the 
culture was harvested by centrifugation at 4600× g for 20 min. The cell pellet was re-suspended in 
0.1× culture volume of 1.5% monosodium glutamate (MSG; w/v in water). The re-suspended culture 
was aliquoted in volumes of 1 mL and stored at −80 °C. 
2.3. Bioreactor-Growth of BCG Vaccine 
The inoculum used for growing batches of BCG for vaccination were prepared as follows: 
Middlebrook 7H10 agar plates were spread with the working seed. These were incubated at 37 °C for 
three weeks. A loopful of growth was used to inoculate 50 mL of Middlebrook 7H9 in five 125 mL 
Erlenmeyer vented flasks. These were incubated for four days at 37 °C whilst shaking at 200 rpm. 
The five BCG cultures were pooled and adjusted to an optical density (OD600 nm) of 1.0 to give a 
total volume of 250 mL of bacilli. Each batch of BCG vaccine consisted of three independent bioreactor 
cultures, grown in Middlebrook 7H9. A large bioreactor (2 L capacity), was inoculated with 100 mL 
of inoculum and two smaller bioreactors (0.8 L capacity) were inoculated with 40 mL of inoculum; 
equating to a 5% v/v of the culture volume. The cultures were agitated by a magnetic bar placed in 
the culture vessel coupled to a magnetic stirrer positioned beneath the vessel. Culture conditions 
were continuously monitored by an Eycoferm Fermentation System (Brighton Systems, Newhaven), 
linked to sensor probes inserted into the culture through sealed ports in the top plate. Culture 
temperatures were monitored using a dual wire stainless steel temperature probe and maintained at 
37 °C by a heating pad positioned beneath the culture vessel. The cultures were stirred at an agitation 
rate of 500 to 750 rpm. The oxygen concentration was monitored with a galvanic oxygen electrode 
(Broadley-James Ltd., Bedford, UK) and the air saturation was maintained at 50% (10% dissolved 
oxygen tension). The initial pH of the cultures was set at 6.7 and was monitored throughout the 
experiment using an Ingold pH electrode (Mettler Toledo, Leicester, UK). All parameters were 
controlled and logged via the Eycoferm controller. Each culture was maintained for ~7 days, at which 
point they were harvested. 
Harvest of BCG 
For the harvest of bioreactor-grown BCG for vaccination, cultures were pooled and spun at 
4600× g for 20 min. The supernatant was decanted, and the pellets were re suspended and pooled in 
approximately 100 mL of 1.5% monosodium glutamate (MSG) (w/v in water). The supernatant was 
spun for a second time at 4600× g for 20 min. The supernatant was discarded, and the pellets were re-
suspended in approximately 20 mL 1.5% MSG before being added to the previous re-suspended 
pellets. To the cell suspension 1.5% MSG was added to a final volume that was equivalent to 10% of 
the original culture volume. The BCG suspension was stored at 4 °C. 
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2.4. Mycobacterium bovis 
The M. bovis strain used for challenge was originally isolated from a naturally infected badger 
in the UK in 1997 (isolate 74/0449/97). All vials of the challenge strain are stored at the Animal and 
Plant Health Agency (APHA) at −80 °C until use at concentration range of 107 to 108 CFU/mL. On the 
day before challenge, one aliquot of the challenge strain was thawed, and submitted to serial dilution 
in sterile water +0.05% tween 80 to obtain approximately 5 × 103 CFU/mL. The dilutions were vortexed 
to diminish the risk of bacterial clumping. The final dilution (challenge inoculum) was made into 
sterile phosphate-buffered saline (PBS) + 0.05% tween 80 and placed inside 3 mL syringes on the day 
prior to the first challenge and kept at +4 °C until all the animals were challenged over the course of 
four days (with one control group challenged on each day). Once each day, the dose of M. bovis 
contained in a syringe was measured retrospectively on three, individual Modified Middlebrook 
7H11 culture plates (100 µL inoculum per plate) placed at 37 °C for four weeks. 
2.5. Badgers 
Forty adult badgers were enrolled in each of two experiments (referred to as Vaccine Efficacy 
Study (VES)9 and VES10, respectively). The animals were trapped from a British county 
(Northumberland) with no reported cases of TB in badgers or cattle and from TB-free areas of two 
other British counties (Yorkshire and Surrey), under the terms of a Natural England licence. Also 
included were badgers born in captivity at APHA from TB-free badgers. Wild, trapped animals were 
confirmed TB-free during a quarantine period when a series of three Interferon Gamma Release 
Assays (IGRA) [15] were conducted at approximately one-month intervals. Clinical samples (tracheal 
mucus and rectal swabs) were negative by culture for M. bovis just after the start of each study. All 
experimental procedures underwent ethical approval by the establishment and were authorised 
under Home Office project licenses PPL70/7878 and P25FCD7D8 with Home Office approved end-
points referring to the welfare of badgers in captivity. No clinical sign associated with experimental 
TB infection was expected nor observed. All procedures (except the delivery of oral vaccine baits 
which were consumed voluntarily) required a general anaesthesia with a cocktail of ketamine, 
butorphenol and medetomidine injected intramuscularly and occasional top ups with isoflurane as 
described previously [16]. Each animal was uniquely identified by a subcutaneous microchip and by 
clip marking to recognize the animal during infra-red (IR) observation by camera. The animals were 
housed in captivity in stable social groups of four animals per pen in an outdoor facility until four to 
six weeks before experimental challenge when they were then moved and housed with the same 
social group to individual rooms within an Advisory Committee on Dangerous Pathogens (ACDP) 
Containment Level 3 (CL3) facility where they were challenged with M. bovis to test the protective 
efficacy of BCG. This period was planned to allow them to acclimatise to their new environment. In 
each facility, individual pens held at least one large wooden box which the badgers could access 
freely and use as a group sett. Between facilities, the badgers were transported conscious, secured 
inside their wooden setts. Objects, such as concrete tunnels and wooden objects were placed in the 
pens as environmental enrichment. Throughout each study, the badgers received a diet of dog food 
(moist and dry) and peanuts. Some of the food was hidden or scattered in the pen to encourage the 
exploratory behaviour of the badgers. Occasionally they were given eggs. Tap water was available 
ad libitum in large trays allowing both bathing and drinking. The badgers were observed daily by 
trained staff members after opening the wooden setts, and regularly using infra-red cameras, in 
particular after the badgers’ initial trapping, transport to CL3 building, and after vaccination and 
challenge. The animals remained in good conditions over the course of the two studies, except for 
two animals (both in the manual vaccination group of VES10, therefore in different pens and social 
groups), which were removed for welfare reasons (unexplained weight loss and a non-treatable 
wound, respectively) before experimental challenge. 
At regular intervals and under general anaesthesia, blood was collected into Vacutainer® serum-
separating tubes, or those containing heparin, and occasionally ethylenediaminetetraacetic acid, 
EDTA, as well as clinical samples (tracheal aspirates, laryngeal swabs and rectal swabs), which were 
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submitted for BCG/M. bovis culture. On these occasions, the clinical condition of each animal was 
recorded. 
2.6. Vaccination 
Badgers were vaccinated with Mycobacterium bovis BCG Danish strain 1331 in 1.5% (w/v) 
monosodium glutamate that had been grown in a bioreactor, harvested and concentrated by 
centrifugation (4600× g, 20 min). Each animal within a social group was randomly allocated to a 
treatment, so that each of the ten pens contained one animal allocated to the control treatment, and 
the remaining three animals allocated to receive vaccine either manually under general anaesthesia 
(VES9 and VES10 studies) or by voluntary consumption of BCG containing baits (in VES10 only). The 
manual vaccination doses of BCG were prepared in sterile conical-bottomed polypropylene 
microcentrifuge tubes. The voluntary consumption vaccination doses were prepared by 
incorporating BCG into a cavity within the badger baits, produced as previously described [8]. 
All vaccine doses, including those in baits, were stored at 2–8 °C until the time of vaccination: 
VES9, 34–35 days’ storage and VES10, 76–84 days’ storage. The manual vaccination of badgers (20 
animals in VES9 and ten in VES10) was conducted under generalised anaesthesia over a single day 
for each study. Each badger received 200 µL BCG, administered using a micropipette as follows: 50 
µL approximately 2 mm above each of the left and right pharyngeal tonsils allowing the suspension 
to percolate over the tonsils and 50 µL under the tongue on each of the left and right sides. After 
vaccination, badgers were monitored closely for approximately five minutes for coughing or signs of 
discomfort (neither observed) and to prevent liquid drainage from the mouth, then returned to their 
wooden setts to recover from general anaesthesia. In VES10, 20 animals each received a fresh single 
BCG bait packaged in a paper bag (approx. 145 × 75 mm) with thin grease-proof lining (Ref 
YPBFERAL, York Paper Company, Auckland, New Zealand; supplied by Connovation Ltd., 
Auckland, New Zealand). Each bag had two holes punched in its top half to assist with the release of 
odour cues to encourage consumption. An additional ten (control) badgers each received a placebo 
bait prepared and presented in the same way as for vaccine bait but containing no BCG. Bait was 
placed in individual cages, each containing a single badger, on up to three separate nights if not 
consumed on the previous occasions. The badger was released from its holding cage each morning. 
To increase the chances of consumption, the badgers had been habituated to consume packaged baits 
(without BCG) before the start of the study. 
The BCG vaccination doses administered to each treatment group were determined using 
samples of the vaccines that had been exposed to the same environmental conditions as the 
administered vaccines. As vaccination in each of the studies took place over several days, BCG doses 
were determined on each vaccination day by titration using Sauton-Tween 80 medium as a diluent 
and by culture on Modified Middlebrook 7H11 agar at 37 °C for 4–5 weeks. 
2.7. Challenge 
Whilst under general anaesthesia, the badgers received 1.35–2.57 × 103 or 1.21–2.50 × 103 CFU in 
1 mL solution in VES9 and VES10, respectively according to the model of endobronchial infection 
with M. bovis developed and reported previously [17]. In this model, the bronchial entrance of the 
right middle lobe was targeted with an endoscope (Olympus fibrescope, 70 cm long, diameter of 3.6 
mm, insertion canal 1.2 mm). M. bovis suspension was instilled through an inner catheter (0.8 mL 
inner volume) inserted within the canal of the endoscope followed by 1 mL of PBS to flush through 
the catheter. After being submitted to experimental challenge, the badgers were laid on their right 
side for recovery from the anaesthesia. 
2.8. Examination Post-Mortem and Scoring of the Severity of the Lesions 
Between twelve to thirteen weeks post-challenge, all the badgers in each study were euthanized 
under general anaesthesia and submitted to a detailed post-mortem examination by pathologists 
blinded to the animals’ treatment. One group of four animals housed in a pen were removed on each 
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day, in random order, over the course of ten working days. Twenty-eight tissues were collected for 
M. bovis culture and for histological examination (lymph nodes–left and right where appropriate: 
parotid, mandibular, retropharyngeal, axillary chain, inguinal chain, popliteal, hepatic, mesenteric, 
anterior mediastinal, bronchial, posterior mediastinal, and tonsils; lung lobes–left and right where 
appropriate: cranial, caudal, middle, accessory; organs: spleen, liver, kidneys; pleura/mediastinum, 
salivary gland, and fat). Complete lungs were immersed in buffered formalin and sliced to explore 
the presence of visible lesions in the parenchyma. 
The severity of the visible TB lesions was described in a standard manner and scored using 
criteria established prior to the first experiment. All data were recorded in a purpose-built database 
for automatic calculation of lesion scores. The level of tuberculous disease was summarized by 
calculating a Disease Burden Score (DBS) [18] once the presence of M. bovis was confirmed by culture 
or by Ziehl Nielsen (ZN) staining in the tissues and when the severity of microscopic lesions was 
determined by histology. 
2.9. Bacterial Culture 
Clinical samples (tracheal aspirates, laryngeal swabs and rectal swabs) were taken from badgers 
under anaesthesia two weeks following vaccination and then every two to three weeks until 
challenge to enable detection of BCG excretion by culture. Collection of clinical samples post-
vaccination only took place for vaccinated animals, not for the controls. Clinical samples were taken 
from two weeks post-challenge until post-mortem and submitted for culture to detect the excretion 
of M. bovis by all (vaccinated and control) badgers, as previously described in [10]. 
2.10. Histology 
Tissues were submitted to histopathology after fixation by immersion in buffered formalin. 
Fixed tissues were blocked into cassettes (up to three tissues, of different types, were inserted per 
wax block) and embedded in paraffin wax. Serial sections four microns thick were cut and stained 
with haematoxylin and eosin stain, and with ZN stain. The severity of granuloma based on their cell 
structure and number of AF bacilli was scored as previously described in [10]. 
2.11. Immune Responses 
Every 2–3 weeks, blood was collected under general anaesthesia to monitor peripheral immune 
responses by measuring the frequency of peripheral blood mononuclear cells (PBMC) producing 
IFNγ by enzyme-linked immune absorbent spot (ELISpot) assay [19] and using an IGRA as 
previously described in [15] to measure the abundance of IFNγ released in culture. Antigens used to 
stimulate PBMC cultures in duplicate wells were those used for the routine diagnosis of TB in humans 
and animals; namely, purified-protein derivative (PPD)B and PPDA (APHA Weybridge antigens). 
Concanavalin-A (ConA) was included in the ELISpot assay and IGRA as a positive control (mitogen) 
for PBMC ability to produce IFNγ. 
2.12. Statistics 
For analysis, ELISpot responses of PBMCs after stimulation by PPDB and PPDA antigens were 
log transformed to make their variance more uniform, using the transformation of raw data log10(x + 
1), which was equivalent to log10(x + 5) in units of spot forming units/106 cells. Transformation of the 
data was applied before duplicate measurements for each antigen were averaged. IGRA responses 
were also log transformed for the same reasons using log10(x − 0.047). All observed values were > 
0.047, but many were close to that minimum value, and preparatory analysis found that the lowest 
observed values should be reduced to near zero before taking their logarithm to minimize skewness 
of the distribution of values after transformation. There were some inconsistent zero and low values 
from ELISpot, so observations were treated as missing if PPDB or PPDA values were <1.1 after 
transformation and averaging, while observations at other time points were consistently >1.7. One 
observation from VES9 at day 14, one observation from VES10 at day 77, and four observations from 
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VES10 at day 91 were interpreted as missing by these criteria. In most cases, both PPDB and PPDA 
values were interpreted as missing., The one exception to this was the observation from VES10 at day 
77, for which PPDB was interpreted as missing but not PPDA. 
Four measurements by ELISpot and IGRA were taken between vaccination and challenge: in 
VES9 at days 14, 28, 70, and 91 after vaccination; in VES10 at days 28, 49, 77, and 91. Measures tended 
to peak early and slowly decrease over each of these periods, but the change was small relative to the 
variance at each time point. For this reason, and since the average of the four time points was expected 
to be a better summary value than a single observation, indicator values were calculated by taking 
the two means across the four time points. The averages for each antigen between vaccination and 
challenge were referred to as PPDBm and PPDAm. 
The measure of disease, DBS, was derived from four measures of tuberculous disease as 
described by [18]: (1) a visible lesion score (VLS) based on the size and distribution of visible lesions 
once the presence of M. bovis was confirmed by culture or by ZN staining of the tissues; (2) a tissue 
count (the number of tissues with TB lesions confirmed by culture or ZN staining); (3) a granuloma 
score derived from H & E stained, formalin-fixed tissue; (4) the total surface area (in mm2) of lung 
with visible lesions estimated at post-mortem. The calculation of DBS included the transformation 
and standardization of each of the four component measures to zero mean with unit variance among 
observations on control badgers accumulated across multiple studies subjected to equivalent 
challenge and necropsy protocols, before calculating DBS for each badger as the sum of the four 
components, as described in [18]. 
The primary comparison of each study was to compare DBS between treatments, taking account 
of any other factors that potentially had a significant effect, including sex, weight at the time of 
vaccination, and group effects as identified by the pens occupied by badgers. Sex and weight had 
been identified as significant factors in a previous, larger preparatory analysis [18]. However, factors 
apart from treatment were excluded because they made no improvement to linear models of the 
individual studies. In VES9, the comparisons of two orthogonal contrasts were planned: the contrast 
between the control treatment and both vaccination treatments, and the contrast between the high 
and low dose vaccination treatments. In VES10, the primary contrast was between the control and 
vaccine bait treatments. Two comparisons were made: (1) including all badgers in the vaccine bait 
treatment, whether they consumed bait or not (evaluation based on intention to treat); and (2) 
excluding badgers that refused bait (evaluation based on exposure to vaccine in bait). Further 
analysis, using ANOVA and linear regression, was combined for VES9 and VES10, since both studies 
had similar designs and the control treatments and manual vaccination treatments matched across 
them. 
Linear regression analysis was applied to estimate the dependence of DBS on PPDBm, PPDAm, 
and treatment. Other covariates including sex, weight at the time of vaccination, and group effects as 
identified by the pens occupied by badgers were considered for inclusion in models, but only sex was 
included because other covariates did not improve model fit. In these analyses, which were primarily 
concerned with the relationship between protection and immunology after vaccination, badgers that 
refused vaccine bait were treated as equivalent to additional controls. 
Survival curve analysis for the M. bovis excretion data was performed by the Log-rank (Mantel-
Cox) test using GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla, CA, USA, 
www.graphpad.com. 
3. Results 
3.1. Vaccine Doses 
The average CFU/mL of the two bioreactor-grown M. bovis BCG batches used for vaccination in 
studies VES9 & VES10 is presented in Table 1, for the pooled harvests of each BCG batch and the final 
concentrated suspensions. These resulted in doses of BCG delivered to each treatment group in each 
experiment shown in Table 2. In VES10, 18/20 badgers offered bait containing vaccine consumed it. 
The two badgers that refused bait were in different groups. In addition, two badgers had to be 
Pharmaceutics 2020, 12, 782 8 of 23 
removed from VES10 for welfare reasons unrelated to treatment. Both were in the manual vaccination 
treatment, and one was in the same pen as a badger that refused vaccine bait. 
Table 1. The average CFU/mL of M. bovis Bacillus of Calmette and Guérin (BCG) used for vaccination 
in studies VES9 & VES10 for the pooled harvest for each BCG batch and the final, concentrated, 
suspension. 
Batch CFU/mL ± SD 
VES9  
Harvest 1.04 × 109 ± 1.35 × 108 
Final 4.64 × 109 ± 2.20 × 108 
VES10  
Harvest 4.40 × 108 ± 1.50 × 108 
Final 2.53 × 109 ± 6.40 × 108 
Table 2. Details of treatment groups in the two experiments: mean vaccine doses and method of 
vaccination. 
Study BCG Dose (CFU) Method of Vaccination Number of Badgers 
VES9 
2.0 × 108 Manual 20 
1.2 × 109 Manual 10 
None N/A 10 
VES10 
8.4 × 108 Manual 8 (originally 10) 
8.6 × 108 Bait 20 
None Placebo bait 1 10 
1 Bait prepared and presented in the same way as vaccine baits but containing no BCG. 
3.2. Vaccine Efficacy as Determined by the Disease Burden Score (DBS) 
Table 3 and Table 4 show the values of DBS for each badger in VES9 and VES10 respectively, 
along with the raw values before transformation of each of the four component measures. The VLS 
and granuloma score for each individual tissue for each badger in VES9 and VES10 are provided as 
Supplementary Spreadsheets S1 and S2, respectively. 
Table 3. Burden of disease for each animal post mortem in VES9, as assessed by four different 
measures, as described above. 
Treatment Badger ID VLS Tissue count Granuloma score VL surface area 1 (mm2) DBS 2 
Control 
NEC-077 10 19 18 300 0.79 
NEC-110 11 13 14 678 2 
NEC-261 5 6 10 20 −4.58 
NEC-293 11 10 14 474 1.53 
NEC-338 5 5 6 190 −4.71 
NEC-541 5 13 11 269 −1.81 
NEC-5591 7 8 10 248 −1.03 
NEC-606 8 8 15 153 −1.38 
NEC-616 0 3 1 2 −13.12 
NEC-9353 8 13 16 602 1.45 
HD 3 
NEC-001 4 2 4 180 −5.19 
NEC-049 14 11 20 91 0.9 
NEC-1081 3 6 9 13 −5.95 
NEC-113 2 8 6 61 −5.5 
NEC-326 6 7 14 84 −2.65 
NEC-351 1 3 6 22 −7.76 
NEC-5012 1 5 0 4 −11.68 
NEC-514 3 4 8 14 −6.51 
NEC-782 4 4 13 17 −4.49 
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NEC-808 7 8 16 52 −1.98 
LD 4 
NEC-035 6 8 14 345 −1.05 
NEC-041 1 4 9 1 −7.68 
NEC-1856 1 6 11 7 −7.13 
NEC-257 4 2 5 140 −5.64 
NEC-2576 1 4 8 75 −6.43 
NEC-260 7 6 12 13 −4.21 
NEC-315 5 7 10 90 −3.5 
NEC-325 4 6 16 4 −4.78 
NEC-337 9 8 13 274 −0.19 
NEC-349 0 2 3 0 −11.62 
NEC-371 4 4 7 45 −5.74 
NEC-373 6 6 7 220 −3.56 
NEC-524 6 3 6 114 −4.53 
NEC-622 6 7 9 117 −3.85 
NEC-7073 2 2 5 0 −8.54 
NEC-772 1 2 2 0 −12.41 
NEC-774 4 8 6 236 −3.6 
NEC-817 1 3 7 145 −5.98 
NEC-889 2 2 4 2 −10.05 
NEC-9262 3 2 5 27 −6.93 
1 Surface area may be zero if visible lesions were not found in the lung, only in other tissues. 2 DBS: 
Disease Burden Score, calculated from the first four variables shown as per [18]. 3 HD: Manual 
vaccination with 1.2 × 109 CFU BCG. 4 LD: Manual vaccination with 2.0 × 108 CFU BCG. 
Table 4. Burden of disease for each animal post mortem in VES10, as assessed by four different 
measures, as described above. 
Treatment Badger ID VLS Tissue count Granuloma score VL surface area 1 (mm2) DBS 2 
Bait 
NEC-1589 5 8 14 350 −0.76 
NEC-1624 9 7 13 221 −1.01 
NEC-2298 6 6 9 468 −1.18 
NEC-2863 5 4 11 62 −3.37 
NEC-2885 1 2 3 4 −9.59 
NEC-289 17 11 23 298 3.24 
NEC-327 6 5 7 839 −1.46 
NEC-3587 1 3 8 42 −7.37 
NEC-3856 10 10 15 121 −0.17 
NEC-5537 14 8 17 537 2.19 
NEC-5593 9 9 12 470 0.34 
NEC-5790 0 2 2 3 −12.01 
NEC-6283 2 2 4 4 −9.26 
NEC-6773 8 7 13 246 −1.11 
NEC-768 4 11 12 185 −3.04 
NEC-7879 1 4 8 232 −5.22 
NEC-833 9 6 8 354 −1.63 
NEC-8375 8 4 6 178 −3.99 
NEC-859 10 9 18 211 0.6 
NEC-9836 11 8 16 196 −0.65 
Control 3 
NEC-2560 7 6 9 82 −3.56 
NEC-3087 8 7 12 89 −2.71 
NEC-4042 5 6 10 260 −3.04 
NEC-4280 6 9 13 66 −3.01 
NEC-523 4 7 12 75 −2.64 
NEC-7066 9 9 13 144 −1.83 
NEC-7368 4 9 18 11 −3.44 
NEC-7525 16 13 18 570 2.97 
NEC-8072 3 7 14 195 −2.42 
NEC-882 10 7 16 293 −0.04 
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Manual 
NEC-263 0 2 1 0 −14.2 
NEC-310 11 7 10 86 −2.09 
NEC-3620 3 4 7 36 −6.25 
NEC-4028 0 2 4 0 −11.29 
NEC-595 1 2 2 0 −10.67 
NEC-6109 5 6 4 36 −5.65 
NEC-7268 1 8 15 12 −5.12 
NEC-372 4 3 4 4 −7.91 
1 Surface area may be zero if visible lesions were not found in the lung, only in other tissues. 2 DBS: 
Disease Burden Score, calculated from the first four variables shown as per [18]. 3 Bait prepared and 
presented in the same way as vaccine baits but containing no BCG. 
The planned comparisons in VES9 found that average DBS was significantly reduced in badgers 
vaccinated manually, i.e., vaccine provided protection, but there was no significant difference 
between the protection from vaccine delivered at low dose and high dose (Table 5). VES10 confirmed 
that DBS was again significantly reduced in badgers vaccinated manually. However, DBS was not 
significantly affected by bait vaccination, whether or not badgers that refused bait were included in 
the comparison. 
Table 5. Planned comparisons of Disease Burden Score (DBS) between treatments. 
Study Comparison Contrast Std. Error 95% Confidence Interval 1  
VES9 
Vaccine vs. Control −3.39 1.34 −6.10 to −0.68 
High dose vaccine vs. Low dose 0.79 1.4 −2.04 to 3.62 
VES10 
Bait vaccine (all) vs. Control −0.8 1.4 −3.64 to 2.04 
Bait vaccine (consumed) vs. Control −0.89 1.46 −3.85 to 2.08 
Manual vaccine vs Control −5.93 1.75 −9.50 to −2.36 
1 Significant where the interval does not span zero. 
Figure 1 shows the DBS values from both studies, separated by treatment (control, bait 
vaccination, manual vaccination). The control and ‘Manual vaccine’ treatments were common to 
VES9 and VES10. The distribution of DBS values for these two treatments intermingled between the 
studies, showing that the two studies were highly reproducible in terms of challenge with M. bovis 
and manual vaccination with BCG. As suggested by visual comparison of observations in the control 
and manual vaccination treatments, analysis of variance found no evidence of a significant difference 
in DBS between VES9 and VES10. Therefore, we treated all the groups from VES9 and VES10 as if 
they were in a single large study. Observations from VES9 and VES10 were combined to provide 
more power to investigate treatment effects. 
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Figure 1. Disease Burden Score (DBS) plotted for each of the different treatments across VES9 (black 
dots) and VES10 (red dots). Controls were unvaccinated. The remaining badgers were either 
vaccinated by voluntary consumption of Bacillus of Calmette and Guérin (BCG) in bait (Bait vaccine, 
open dots refused bait) or by manual vaccination with 2.0 × 108 colony forming units (CFU) (VES9) or 
8.4 × 108 CFU (VES10) BCG (plotted collectively as ‘Manual vaccine’) or with a higher dose (1.2 × 109 
CFU) of BCG in VES9 only (plotted as ‘High dose manual’). Bars indicate mean with its 95% 
confidence interval. 
Combining the observations of VES9 and VES10, and assuming the manual vaccination 
treatments had equivalent effects to each other, we estimated the effect of manual vaccination with a 
narrower confidence interval (compare Table 6 with Table 5). The three manual vaccination 
treatments across the two studies did not significantly differ from each other (Table 6). The effect of 
bait vaccine relative to controls was still not statistically significant after pooling the studies. The 
difference between sexes was similar to the difference reported from previous studies [18], although 
its significance here was marginal (P = 0.06). 
Table 6. Treatment and sex effects from an analysis of variance of Disease Burden Score (DBS) across 
VES9 and VES10. Badgers that refused vaccine bait have been excluded from this analysis. 
Source Value Std. Error P 95% Confidence Interval 
Treatments     
Bait vaccine vs. control −1.02 1.17 0.39 −3.34 to 1.31 
Manual vacc. vs. control −4.23 0.99 <0.001 −6.22 to −2.25 
High dose vs. Low dose VES9 0.95 1.38 0.49 −1.81 to 3.70 
VES10 vs. Low dose VES9 −1.91 1.49 0.21 −4.88 to 1.06 
Sex     
Male vs. female 1.6 0.85 0.06 −0.10 to 3.30 
3.3. Excreted BCG or M. bovis within Clinical Samples 
Clinical cultures were sown onto six 7H11 slopes at 2, 4, 10, and 13 weeks post-vaccination in 
both studies, and at 2, 5, 8, and 12 weeks post-challenge for culture of BCG and M. bovis in VES9 and 
at 2, 4, 7, 12, and 13 weeks post-challenge in VES10. Results are shown in Table 7; Table 8 for VES9 
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and in Table 9 only for VES10, as no BCG was found in clinical samples in VES10. BCG was excreted 
into the larynx and trachea post-vaccination, but not into faeces in VES9 (Table 7). 
Table 7. Clinical samples from VES9 that yielded a positive Bacillus of Calmette and Guérin (BCG) 
culture 1, derived from badgers that received the higher dose of BCG manually 2. 
Badger ID 
Weeks after vaccination 
2 weeks 4 weeks 10 weeks 13 weeks 3 
NEC-001 LS LS LS 
 
NEC-049 TA LS, TA  
NEC-1081    
NEC-113    
NEC-326 LS LS  
NEC-351  LS TA 
NEC-5012    
NEC-514 LS LS, TA  
NEC-782 LS   
NEC-808    
1 LS = laryngeal swab; TA = tracheal aspirate. 2 No BCG excretion was detected from control badgers 
nor those vaccinated manually with the lower dose of BCG in VES9. 3 Day of challenge with M. bovis–
no BCG was cultured from any clinical sample on this occasion. 
M. bovis was excreted, mostly in the tracheal mucus, and without any initial clear pattern of 
differences between manual vaccinated and controls (Tables 8 and 9). Figure 2 presents the excretion 
data for both experiments as survival curves. M. bovis excretion tended to occur in a greater 
proportion of control badgers and at an earlier time point than vaccinated badgers in both studies. 
However, when these data were subjected to statistical analysis (Log-rank (Mantel–Cox) test), no 
significant difference was found between the curves in either VES9 (p = 0.2299) or VES10 (p = 0.5104). 
Table 8. Clinical samples from VES9 that yielded a positive M. bovis culture 1. 
Treatment Badger ID 
Weeks after challenge with M. bovis 
2 weeks 5 weeks 8 weeks 12 weeks 2 
Control 
NEC-077  
TA 
  
NEC-110    
NEC-261    
NEC-293    
NEC-338    
NEC-541 LS, TA   
NEC-5591    
NEC-606 TA  LS, TA 
NEC-616    
HD 3 
NEC-9353 TA   
NEC-001    
NEC-049    
NEC-1081    
NEC-113  TA  
NEC-326    
NEC-351    
NEC-5012    
NEC-514    
NEC-782    
NEC-808    
LD 4 
NEC-035  LS, TA  
NEC-041    
NEC-1856    
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NEC-257 TA   
NEC-2576    
NEC-260    
NEC-315    
NEC-325    
NEC-337  LS, TA  
NEC-349    
NEC-371    
NEC-373 LS, TA  TA 
NEC-524    
NEC-622    
NEC-7073    
NEC-772    
NEC-774  LS  
NEC-817    
NEC-889    
NEC-9262    
1 LS = laryngeal swab; TA = tracheal aspirate. 2 Day of post-mortem. 3 HD: Manual vaccination with 
1.2 × 109 CFU BCG. 4 LD: Manual vaccination with 2.0 x 108 CFU BCG. 
Table 9. Clinical samples from VES10 that yielded a positive M. bovis culture 1. 
Treatment Badger ID 
Weeks after challenge with M. bovis 
2 weeks 4 weeks 7 weeks 12 weeks 13 weeks 2 
Bait 
NEC-1589   TA   
NEC-1624 RS   LS  
NEC-2298      
NEC-2863      
NEC-2885      
NEC-289    TS, TA  
NEC-327      
NEC-3587      
NEC-3856      
NEC-5537   LS, TA LS, TA  
NEC-5593     LS 
NEC-5790      
NEC-6283      
NEC-6773   LS, TA   
NEC-768     F, RS, TA 
NEC-7879      
NEC-833      
NEC-8375      
NEC-859     TS, TA 
NEC-9836    LS  
Control 3 
NEC-2560      
NEC-3087      
NEC-4042  TA    
NEC-4280      
NEC-523      
NEC-7066  TA LS, TA LS, F, TA  
NEC-7368   TA   
NEC-7525   LS LS  
NEC-8072  LS TA   
NEC-882      
Manual NEC-263      
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NEC-310      
NEC-3620   TA TA  
NEC-4028      
NEC-595      
NEC-6109      
NEC-7268  LS TA   
NEC-372      
1 TA = tracheal aspirate; RS = rectal swab; LS = laryngeal swab; TS =tracheal swab; F = faecal swab. 2 
Day of post-mortem. 3 Bait prepared and presented in the same way as vaccine baits but containing 
no BCG. 
 
(a) (b) 
Figure 2. Survival curves showing the percentage of each treatment group in study VES9 (a) and 
study VES10 (b) excreting M. bovis in any clinical sample at the time that the first positive culture was 
produced. Controls = unvaccinated badgers. HD = manual vaccination with 1.2 × 109 colony forming 
units (CFU) of Bacillus of Calmette and Guérin (BCG). LD = manual vaccination with 2.0 × 108 CFU 
BCG. Bait = vaccinated with 8.6 × 108 CFU BCG by voluntary consumption of BCG in bait. Manual = 
manual vaccination with 8.4 × 108 CFU BCG. 
3.4. Immune Responses 
Cellular immune responses were assessed over the time course of VES9 and 10 by IFNγ direct 
ELISpot (Figure 3) and IFNγ enzyme-linked immunosorbent assay (ELISA) (IGRA) from stimulated 
cultures of PBMCs (Figure 4). The ELISpot response of PBMCs to ConA fluctuated throughout the 
study, dipping in particular on the day of post-mortem in VES9, as we have observed in other VES 
studies [10]. Importantly however, this did not prevent the response of PBMCs to antigens. The IGRA 
response to ConA was less variable in general over time compared to the ELISpot. ConA responses 
did not differ significantly between treatment groups at any time point in either study or in either 
assay. 
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Figure 3. Interferon-gamma (IFNγ) direct enzyme-linked immune absorbent spot (ELISpot) assay 
results for VES9 left and VES10 right, for each of the stimulations shown (ConA = concanavalin A. 
Error bars are standard errors of the means. 
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Figure 4. Peripheral blood mononuclear cells (PBMC) interferon-gamma (IFNγ) enzyme-linked 
immunosorbent assay (ELISA) (IGRA) for VES9 left and VES10 right, for each of the stimulations 
shown (ConA = concanavalin A). Error bars are standard errors of the means. 
Antigen-specific responses appeared broadly comparable between assays in each study. 
Responses to both PPDA and PPDB between vaccination and challenge tended to be greater in 
badgers receiving manual vaccination than in other treatments (Figures 3 and 4). On the other hand, 
responses to PPDB increased after challenge more in controls and the bait vaccination treatment. A 
similar but weaker change was observed after challenge in the response to PPDA. The net effect was 
that PPDA and PPDB responses after challenge were often similar across treatments. 
The PPDAm and PPDBm values, calculated as explained in the Methods from ELISpot and 
IGRA were used as summaries of the PPDA and PPDB responses post-vaccination up to challenge. 
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The correlation between the two responses and their dependence on treatment is displayed as a point 
for each individual animal in Figure 5. Despite individual variation, a clear association could be seen 
between vaccine given manually and the pre-challenge IFNγ response, which even provided some 
discrimination between manual vaccination treatments. The IFNγ response in the Bait vaccination 
treatment mostly mingled with the control treatment but had a wide range that overlapped with the 
manual vaccination treatments more than the controls did, especially in the IGRA plot (Figure 5b). 
PPDAm and PPDBm were strongly correlated with each other, but linear discriminant analysis found 
that PPDBm was more important in differentiating the treatments (Table 10). 
 
 
Figure 5. Measures of post-vaccination reaction to purified-protein derivative (PPD)A and PPDB 
measured by (a) enzyme-linked immune absorbent spot (ELISpot) assay and (b) IGRA, and 
transformed and summarised to PPDAm and PPDBm as described in the Methods. Each point 
summarises the post-vaccination state of one badger. 
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Table 10. Standardised loadings of PPDAm and PPDBm in the primary discriminant from a linear 
discriminant analysis between treatment groups in VES9 and VES10 (Stata 15 ‘candisc’ command). 
The magnitude of these loadings can be understood as formal measures of the relative contributions 
made to differentiating vaccination treatments, i.e., PPDBm was the main measure of treatment effect 
on immunology, especially when measured by enzyme-linked immune absorbent spot (ELISpot) 
assay, whereas the association of PPDAm with treatments was mainly due to its correlation with 
PPDBm. The data used in this analysis are displayed in Figure 5. 
Method PPDAm Loading PPDBm Loading 
ELISpot 0.017 0.987 
IGRA 0.217 0.830 
Comparing Figure 5a with Figure 5b also demonstrates that, despite the consistency between 
the ELISpot and IGRA observations (correlation coefficients: PPDAm 0.852, PPDBm 0.863), the 
different methods produce measures with different scaling. The resolution of ELISpot measures is 
relatively high at low values, separating control observations while bunching observations from 
vaccinated treatments, while IGRA measures have higher resolution at high values. Partly because 
they are both log-transformed, the two measures have similar range and variance, so a combined 
measure with more uniform resolution can easily be generated by adding together matching pairs of 
ELISpot and IGRA measurements, which will be referred to as ‘combined’ PPDAm and PPDBm. 
Although the DBS values were visibly correlated overall with the combined PPDBm data 
(ELISpot plus IGRA) from both studies (Figure 6), PPDBm distinguishes treatments so well, the 
differences between treatments explain most of the relationship between DBS and PPDBm (see 
‘manual vaccine v. control’ in Table 11). The exception is for the bait vaccination treatment, where 
there was a highly significant association between DBS and PPDBm for individual animals within 
the Bait vaccination treatment (Figure 6, ‘slope v. PPDBm’ in Table 11). Hence, where PPDBm was 
close to zero in bait vaccinated animals the DBS was similar to controls, but where higher values of 
PPDBm were observed in bait vaccinated animals the DBS was reduced compared to controls, 
indicating a degree of protection. In total, six badgers in the bait treatment group had higher 
combined PPDBm than the other twelve that ingested baits, and five of those six had lower DBS than 
other badgers in the group (Figure 6, see also Figure 1). The implication was that vaccine delivery 
varied within the Bait vaccine treatment, so that a minority of badgers (no more than six) were 
effectively vaccinated and protected against TB. The bait treatment group could in effect be classified 
by their PPDBm response into a majority (two-thirds) that responded to challenge like controls, and 
a minority (one-third) that responded like badgers receiving manual vaccination. 
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Figure 6. Disease Burden Score (DBS) of badgers post mortem plotted against purified-protein 
derivative (PPD)B reaction post-vaccination (PPDBm), from a combination of log-transformed 
enzyme-linked immune absorbent spot (ELISpot) assay and IGRA measures. Observations are 
classified into five treatment groups as in the legend. The line is fitted to the observations from the 
bait vaccination treatment only (P = 0.0003); although the trend roughly matches the differences 
between treatments, there was no significant trend related to PPDBm within the other treatments 
(Table 11). 
Table 11. Analysis of variance of Disease Burden Score (DBS) using combined PPDBm as the only 
measure of post-vaccination immunology. 
Parameter Estimate Std. Err. t Ratio Prob > t 95% Confidence Interval 
Manual vaccine v. Control −4.54 1.32 −3.45 0.007 −7.16 to −1.92 
Bait      
Intercept v. Control 1 0.09 1.10 0.08 0.94 −2.10 to 2.28 
Slope v. PPDBm 2 −2.71 0.87 −3.11 0.003 −4.44 to −0.98 
General slope v. PPDBm 3 0.14 0.55 0.26 0.80 −0.95 to 1.24 
Male v. Female 1.49 0.80 1.87 0.07 −0.10 to 3.08 
1 The difference between Bait vaccination and Control treatments at combined PPDBm = 0. 2 Slope of 
the regression of DBS against combined PPDBm within the Bait vaccination treatment. 3 Slope of a 
regression of DBS against combined PPDBm within Control and Manual vaccination treatments. 
When the regression model included the combined PPDAm measure as well as PPDBm, the 
treatment differences remained broadly the same as with PPDBm alone, but some variation within 
treatments was associated with the difference between PPDBm and PPDAm (Table 12). DBS was 
generally negatively associated with PPDBm and positively associated with PPDAm, with an even 
stronger negative association with PPDBm in the bait vaccination treatment (Table 12). Hence, the 
magnitude of the post-vaccination IFNγ response before challenge was indicative of both successful 
vaccine delivery and some protection against challenge. The response to PPDB was the main 
discriminator between vaccine treatments and of vaccine delivery, while the response to PPDA 
relative to PPDB indicated variation within treatments. Note that a recent analysis of previous badger 
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vaccination studies identified a similar relationship within treatments between DBS and PPDA 
response before vaccination [18]. However, it is notable that including PPDAm in the model had little 
impact on the estimated average treatment effects (compare Tables 11 and 12). 
Table 12. Analysis of variance of Disease Burden Score (DBS) using combined PPDAm as well as 
PPDBm to measure post-vaccination immunology. 
Parameter Estimate Std. Err. t Ratio Prob > t 95% Confidence Interval 
Manual vaccine v. Control −4.24 1.22 −3.45 0.001 −6.67 to −1.81 
Bait      
Intercept v. Control 1 −0.18 1.02 −0.18 0.86 −2.21 to 1.85 
Slope v. PPDBm 2 −2.32 0.81 −2.86 0.006 −3.94 to −0.70 
General slope v. PPDAm 3 2.40 0.66 3.63 0.001 1.08 to 3.72 
General slope v. PPDBm 3 −1.82 0.74 −2.45 0.02 −3.30 to −0.34 
Male v. Female 1.23 0.74 1.66 0.10 −0.25 to 3.08 
1 The difference between Bait vaccination and Control treatments at combined PPDBm = 0. 2 Slope of 
the regression of DBS against combined PPDBm within the Bait vaccination treatment only. 3 Slope of 
a regression of DBS against combined PPDAm or PPDBm within all treatments, i.e., fitting parallel 
lines with the same slope within each treatment. 
4. Discussion 
The studies presented here were planned to test the protective efficacy granted by oral 
bioreactor-grown BCG delivered by two different methods: (a) via the ingestion of a vaccine-bait 
product; and (b) by direct administration into the mouth under general anaesthesia. One key finding 
in the first study (VES9) was the ability of bioreactor-grown BCG to confer significant protection to 
badgers against M. bovis challenge via direct administration at a dose of at least 2.0 × 108 CFU. The 
protection seen in VES9 with oral bioreactor-grown BCG was replicated in VES10 by the manual 
route. This result confirms what has been observed previously, that the oral route is suitable for 
protecting badgers against virulent M. bovis [10,11,20,21]. 
A second outcome of the studies was that BCG presented in voluntarily-consumed baits did not 
result in demonstrable protection at the group-level. However, detailed analysis suggested that 
vaccine was successfully delivered to and potentially protected no more than six out of 18 badgers 
that ingested baits. Whilst we do not know the crucial site(s) for immune induction following the 
administration of oral BCG, the results with manual vaccination suggest that delivery to the tonsils 
and underlying lymphoid-associated tissue of the oropharynx may be enough to induce protective 
immunity. This is supported by our recently published observations that following manual 
vaccination of badgers, significant quantities of live BCG were taken up by the tonsils, persisting in 
local lymphoid tissues of vaccinated badgers for at least eight weeks and inducing circulating IFNγ-
producing mononuclear cells [22]. Whilst we cannot rule out a role for immune induction occurring 
through uptake of swallowed BCG via the intestines, we know uptake of live BCG to be less efficient 
when administered directly to the ileum [22]. Collectively, these data cause us to hypothesise that the 
limiting step for efficient bait vaccination is release of BCG into the mouth of the badger when bait 
vaccine is consumed. Previous unpublished observations of wild badgers exposed to the bagged bait 
used in this work showed that individuals spent on average 55 s (36 to 100 s, n = 5) consuming the 
bait (Defra research project SE3246), which is a relatively limited window of opportunity if indeed 
this is the most significant factor effecting the efficacy of oral bait vaccination of badgers. A similar 
situation was observed in the evaluation of an oral bait vaccine against rabies, where bait placed a 
constraint on the full release of the contained dose. Following 13 vaccine studies, it became clear that 
a higher dose of rabies vaccine was required in bait to achieve a similar level of protection to that 
administered manually [23]. This is significant, since the site of immune induction following oral 
rabies vaccination appears to be the oral cavity and not the intestine, at least based on where the 
vaccine replicates and can be detected [24]. Under a logical step-wise approach, future experiments 
would examine the delivery system in detail and allow for a re-design that would mimic, as closely as 
possible, the direct administration method. It is not unreasonable to hypothesise that in many cases the 
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current bait design, which has a small volume of BCG in a relatively large bait-carrier mass [8], results 
in the mixing of the BCG in the bait during chewing with the result that most of it is swallowed. 
We observed that antigen-specific IFNγ responses after vaccination were related to the degree 
of protection as expressed by DBS at the end of each study; protection being positively associated 
with the magnitude of the PPDB response. It was the general case, however, that PPDB responses were 
more discriminatory at the level of vaccine treatment than for individual animals. Study of the 
vaccination of cattle with BCG have concluded that post-vaccination antigen-specific IFNγ levels in 
whole blood are not always a reliable indicator of protection against a subsequent virulent challenge 
[25,26], although when PBMC were isolated from BCG-vaccinated calves immediately prior to M. 
bovis challenge and cultured in the presence of antigen and IL-2 to establish short-term T cell lines, 
the frequency of antigen-specific IFNγ-secreting memory cells did correlate with protection [27]. 
Beyond species differences, discrepancies between studies in respect to pre-challenge immune 
correlates of protection are likely to arise not only from the conditions of the assay (ex vivo versus 
cultured PBMC) but also the way the immunological data are treated before statistical analysis. For 
example, in [26], the authors looked to correlate the maximal quantity of IFNγ (expressed as ng/mL 
by IGRA) induced by vaccination with the degree of protection, whereas in [27] it was the frequency 
of IFNγ-secreting cells by ELIspot at a single time point. In our case, we not only took an average of 
all (four) time points post-vaccination but used a combination of ELISpot (frequency of IFNγ-
producing cells per mL blood) and IGRA data, and log-transformed the data before analysis to 
improve the homogeneity of variance and to improve the linearity of the data so that the averaging 
could be beneficial. Of these differences, we suspect the averaging of the post-vaccination response 
was most important, since in a different cattle study the authors found that neither the levels of IFNγ 
detected by ELISA nor detected by ELISpot in individual vaccinated animals at the time of challenge 
correlated with subsequent resistance [25]. Note that the strong correlation found between average 
values from ELISpot and from IGRA in our study suggests that the data preparation substantially 
improved precision. This is an approach that should be considered in future vaccination-protection 
studies of TB and could even be applied retrospectively to existing data. In any case, the immune 
responses reported here are evidence of efficient exposure of badgers to the vaccine. In the bait 
vaccination treatment group, which overall did not achieve a statistically significant decrease in DBS, 
the pre-challenge immunology of around a third of badgers appeared equivalent to those of manually 
vaccinated badgers and with the level of protection observed in those individual badgers, which 
suggests some VES10 animals received a protective dose of BCG through bait delivery. This supports 
our contention that vaccination with the bait in the current design can give protection, but only to a 
minority of badgers that consume it. 
5. Conclusions 
We demonstrated repeatable protection against TB through the direct administration of at least 
2.0 × 108 colony forming units of BCG to the oral cavity of badgers. Vaccination via voluntary 
consumption of bait containing the same preparation of BCG did not result in demonstrable 
protection at the group-level, although there was evidence based on immune responses following 
vaccine bait delivery and pathology post mortem that a minority of badgers (no more than six from 
18) were effectively vaccinated and protected against TB through bait delivery. The need to deliver 
oral BCG in the context of a palatable and environmentally robust bait appears to introduce such 
variation in BCG delivery to sites of immune induction in the badger as to render experimental 
studies variable and inconsistent. This currently poses the biggest impediment to the introduction of 
a robust oral bait vaccine against TB in badgers in the UK. 
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